ProMIS Neurosciences

ProMIS Neurosciences Intangible Assets

Intangible Assets of ProMIS Neurosciences (PMN) as of Oct 27, 2026.

Intangible Assets

0.00USD

Last updated:

Intangible Assets of ProMIS Neurosciences is 2023 0.00 USD. Intangible Assets of ProMIS Neurosciences was 2022 20,000.00 USD. It decreases by % lower compared to the previous year.

The ProMIS Neurosciences Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2016
50,000.00 USD
Jan 1, 2017
50,000.00 USD
Jan 1, 2018
40,000.00 USD
Jan 1, 2019
40,000.00 USD
Jan 1, 2020
30,000.00 USD
Jan 1, 2021
30,000.00 USD
Jan 1, 2022
20,000.00 USD
Jan 1, 2023
0.00 USD
The ProMIS Neurosciences Intangible Assets history
YEARIntangible AssetsYoY
0.00USD-100.00%
20,000.00USD-33.33%
30,000.00USD0.00%
30,000.00USD-25.00%
40,000.00USD0.00%
40,000.00USD-20.00%
50,000.00USD0.00%
50,000.00USD0.00%
50,000.00USD-28.57%
70,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences develops precision medicine solutions targeting neurodegenerative diseases like Alzheimer’s, ALS, and MSA through proprietary antibody therapeutics. Its product portfolio includes PMN310 for amyloid-beta, PMN267 for TDP-43, and PMN442 for alpha-synuclein, leveraging its ProMIS and Collective Coordinates platforms to identify Disease Specific Epitopes on misfolded proteins. The company focuses on early detection and treatment, with plans to expand into Parkinson's and dementia with Lewy bodies. Its wholly owned subsidiary, ProMIS Neuro, supports these therapeutic development efforts. The firm generates revenue through the development and potential commercialization of its antibody therapeutics, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for neurodegenerative conditions. Its focus on misfolded proteins in diseases like AD, ALS, and MSA positions it to address unmet medical needs in specialized therapeutic segments. The company’s approach combines computational discovery with antibody development to create targeted solutions for complex neurological disorders. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProMIS Neurosciences stock

On Eulerpool you can find the complete historical development of Intangible Assets ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's ProMIS Neurosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — ProMIS Neurosciences

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — ProMIS Neurosciences